Skip to main content

Prurigo Nodularis

13
Pipeline Programs
11
Companies
18
Clinical Trials
1 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
4
0
8
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Monoclonal Antibody
675%
Small Molecule
225%
+ 13 programs with unclassified modality

Competitive Landscape

10 companies ranked by most advanced pipeline stage

Incyte
IncyteDE - Wilmington
5 programs
1
1
3
PovorcitinibPhase 3Small Molecule1 trial
PovorcitinibPhase 3Small Molecule1 trial
Ruxolitinib CreamPhase 31 trial
INCB054707Phase 21 trial
Ruxolitinib Cream 1.5%Phase 11 trial
Active Trials
NCT06213831Completed23Est. Jul 2025
NCT05061693Completed146Est. Feb 2024
NCT06516965Active Not Recruiting346Est. May 2027
+2 more trials
Galderma
GaldermaTX - Dallas
5 programs
1
4
NemolizumabPhase 3Monoclonal Antibody1 trial
NemolizumabPhase 3Monoclonal Antibody1 trial
NemolizumabPhase 3Monoclonal Antibody1 trial
Nemolizumab 30 mgPhase 31 trial
CD14152 Dose APhase 21 trial
Active Trials
NCT03181503Completed70Est. Sep 2018
NCT04204616Active Not Recruiting500Est. Oct 2026
NCT04501679Completed274Est. Mar 2022
+2 more trials
Keymed Biosciences
Keymed BiosciencesChina - Chengdu
1 program
1
StapokibartPhase 31 trial
Active Trials
NCT06424470Active Not Recruiting200Est. Jul 2026
Sandoz
SandozAustria - Kundl
1 program
1
PimecrolimusPhase 2
Vyne Therapeutics
Vyne TherapeuticsIsrael - Ness Ziona
1 program
1
serlopitantPhase 21 trial
Active Trials
NCT02196324Completed128Est. Jun 2016
Trevi Therapeutics
Trevi TherapeuticsNEW HAVEN, CT
3 programs
Nalbuphine ER TabletsPHASE_2_31 trial
nalbuphine HCl ERPHASE_2_31 trial
nalbuphine HCl ER tablets 90 mg BIDPHASE_2_31 trial
Active Trials
NCT03497975Completed353Est. Feb 2023
NCT02174432Completed36Est. Sep 2017
NCT02174419Completed62Est. Aug 2016
Celldex Therapeutics
2 programs
CDX-0159PHASE_11 trial
barzolvolimabPHASE_2Monoclonal Antibody1 trial
Active Trials
NCT04944862Completed24Est. Jul 2023
NCT06366750Active Not Recruiting140Est. Mar 2027
Regeneron
RegeneronTARRYTOWN, NY
1 program
DupilumabN/AMonoclonal Antibody
Bristol Myers Squibb
1 program
CC-10004PHASE_21 trial
Active Trials
NCT00869089Completed5Est. Jan 2011
Kiniksa Pharmaceuticals
1 program
VixarelimabPHASE_2Monoclonal Antibody

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
IncytePovorcitinib
IncytePovorcitinib
Keymed BiosciencesStapokibart
IncyteRuxolitinib Cream
GaldermaNemolizumab
GaldermaNemolizumab
GaldermaNemolizumab 30 mg
GaldermaNemolizumab
Trevi TherapeuticsNalbuphine ER Tablets
Trevi Therapeuticsnalbuphine HCl ER
Trevi Therapeuticsnalbuphine HCl ER tablets 90 mg BID
Celldex Therapeuticsbarzolvolimab
IncyteINCB054707
GaldermaCD14152 Dose A
Vyne Therapeuticsserlopitant

Showing 15 of 18 trials with date data

Clinical Trials (18)

Total enrollment: 3,147 patients across 18 trials

NCT06516952IncytePovorcitinib

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)

Start: Oct 2024Est. completion: May 2027330 patients
Phase 3Recruiting
NCT06516965IncytePovorcitinib

A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)

Start: Oct 2024Est. completion: May 2027346 patients
Phase 3Active Not Recruiting
NCT06424470Keymed BiosciencesStapokibart

Study on the Treatment of Prurigo Nodularis With Stapokibart Injection

Start: Jun 2024Est. completion: Jul 2026200 patients
Phase 3Active Not Recruiting
NCT05764161IncyteRuxolitinib Cream

A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)

Start: Jun 2023Est. completion: Nov 2025190 patients
Phase 3Completed
NCT05052983GaldermaNemolizumab

A Study to Evaluate the Durability of Response and Safety of Nemolizumab for 24 Weeks in Participants With Prurigo Nodularis

Start: Jan 2022Est. completion: Sep 202334 patients
Phase 3Completed
NCT04204616GaldermaNemolizumab

A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

Start: Jan 2021Est. completion: Oct 2026500 patients
Phase 3Active Not Recruiting
NCT04501666GaldermaNemolizumab 30 mg

Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

Start: Sep 2020Est. completion: Feb 2023286 patients
Phase 3Completed
NCT04501679GaldermaNemolizumab

A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)

Start: Aug 2020Est. completion: Mar 2022274 patients
Phase 3Completed
NCT03497975Trevi TherapeuticsNalbuphine ER Tablets

PRISM Study-Pruritus Relief Through Itch Scratch Modulation

Start: Aug 2018Est. completion: Feb 2023353 patients
Phase 2/3Completed
NCT02174432Trevi Therapeuticsnalbuphine HCl ER

Open Label Extension Study of Nalbuphine HCl ER in Patients With Prurigo Nodularis

Start: Aug 2015Est. completion: Sep 201736 patients
Phase 2/3Completed
NCT02174419Trevi Therapeuticsnalbuphine HCl ER tablets 90 mg BID

Study of Nalbuphine HCl ER Tablets in Patients With Prurigo Nodularis

Start: Mar 2015Est. completion: Aug 201662 patients
Phase 2/3Completed
NCT06366750Celldex Therapeuticsbarzolvolimab

A Study of Barzolvolimab in Patients With Prurigo Nodularis

Start: Apr 2024Est. completion: Mar 2027140 patients
Phase 2Active Not Recruiting
NCT05061693IncyteINCB054707

A Study to Evaluate the Efficacy and Safety of INCB054707 in Participants With Prurigo Nodularis

Start: Nov 2021Est. completion: Feb 2024146 patients
Phase 2Completed
NCT03181503GaldermaCD14152 Dose A

Safety and Efficacy of Nemolizumab in PN

Start: Oct 2017Est. completion: Sep 201870 patients
Phase 2Completed
NCT02196324Vyne Therapeuticsserlopitant

A Randomized Placebo-Controlled Study of the Neurokinin-1 (NK1) Receptor Antagonist Serlopitant Prurigo Nodularis (PN)

Start: Jul 2014Est. completion: Jun 2016128 patients
Phase 2Completed
NCT00869089Bristol Myers SquibbCC-10004

Safety and Efficacy of CC-10004 for Prurigo Nodularis

Start: Sep 2008Est. completion: Jan 20115 patients
Phase 2Completed
NCT06213831IncyteRuxolitinib Cream 1.5%

A Study to Evaluate the Safety and Tolerability of Maximal Use Ruxolitinib Cream

Start: Feb 2024Est. completion: Jul 202523 patients
Phase 1Completed
NCT04944862Celldex TherapeuticsCDX-0159

A Study of CDX-0159 in Patients With Prurigo Nodularis

Start: Nov 2021Est. completion: Jul 202324 patients
Phase 1Completed

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

8 late-stage (Phase 3) programs, potential near-term approvals
1 actively recruiting trials targeting 3,147 patients
11 companies competing in this space

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.